India · Delayed Price · Currency is INR Sudarshan Chemical Industries Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 delivered robust revenue and EBITDA growth, with strong margin improvement and significant debt reduction. Guidance remains unchanged due to geopolitical uncertainties, but ongoing cost reduction and value capture initiatives are expected to drive further gains.
Fiscal Year 2026
-
Q4 acquired-group business EBITDA exceeded its target as customer buying recovered and inventory fell. FY27 guidance calls for EUR 35 million acquired-group EBITDA, while geopolitical cost and demand uncertainty remain.
-
Q3 was pressured by weak demand and acquired-customer destocking, while cost savings limited losses. Management sees buying recovery and targets EUR 30–40 million of inventory reduction, supporting cash flow but temporarily weighing on reported EBITDA.
-
Soft demand and customer destocking depressed Q2, while acquired-group FY EBITDA guidance fell to EUR 25–30 million. Integration and longer-term guidance remain on track, with a demand recovery expected from Q4.
-
Integration of acquired pigment businesses has stabilized operations and expanded the global footprint, with Q1 revenue at INR 2,507 crore and Adjusted EBITDA at INR 165 crore. Despite market headwinds and customer destocking, management remains confident in achieving growth and margin targets for FY26 and beyond.
Fiscal Year 2025
-
FY25 combined sales reached INR 3,346 crore and adjusted EBITDA INR 402 crore, including one month from the acquired group. Management targets EUR 35 million acquired-group EBITDA in FY26 and EUR 90 million–EUR 100 million in 3–4 years, while prioritizing integration and deleveraging.
-
Q3 FY25 saw 18% revenue growth and improved margins, driven by strong export and specialty pigment sales, while RIECO turned EBITDA positive. Acquisition of Heubach is on track for March 2025, with funding secured and integration costs recognized.
-
Q2 revenue rose 13% YoY as pigment sales reached a record and pigment EBITDA margin expanded to 15.9%. New capacity drove export momentum; the Heubach transaction was expected to close in Q4, with remaining funding planned through debt.
-
Q1 FY25 saw 4% revenue growth and 15% EBITDA increase year-on-year, driven by strong specialty pigment demand and improved margins. Net debt and leverage ratios improved, while management expects sustained gross margins and operational leverage benefits.
Fiscal Year 2024
-
The acquisition adds Heubach’s global footprint, technology and market reach, complementing low-cost manufacturing and existing product strengths. Management targets early savings, significant value capture within a year, and full benefits within two years, subject to approvals.